Thaddeus H Grasela

Summary

Affiliation: Cognigen Corporation
Country: USA

Publications

  1. ncbi Challenges in the transition to model-based development
    Thaddeus H Grasela
    Cognigen Corporation
    AAPS J 7:E488-95. 2005
  2. ncbi Pharmacometrics and the transition to model-based development
    T H Grasela
    Cognigen Corporation, Williamsville, New York, USA
    Clin Pharmacol Ther 82:137-42. 2007
  3. ncbi Informatics: the fuel for pharmacometric analysis
    Thaddeus H Grasela
    Cognigen Corporation, Buffalo, NY 14221 5831, USA
    AAPS J 9:E84-91. 2007
  4. ncbi Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections
    Scott Van Wart
    Pharmacometrics R and D, Cognigen Corporation, Buffalo, New York 14221-5831, USA
    Antimicrob Agents Chemother 48:4766-77. 2004
  5. ncbi Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent
    Alison K Meagher
    Department of Clinical Pharmacology, Cognigen Corporation, Buffalo, NY 14221, USA
    Diagn Microbiol Infect Dis 52:165-71. 2005
  6. ncbi Kerfuffle!
    Thaddeus H Grasela
    Cognigen Corporation, 395 Youngs Road, Buffalo, NY 14221, USA
    J Clin Pharmacol 49:386-8. 2009
  7. ncbi Exposure-response analyses of tigecycline tolerability in healthy subjects
    Julie Passarell
    Pharmacologic Division, Cognigen Corporation, Buffalo, NY 14221, USA
    Diagn Microbiol Infect Dis 65:123-9. 2009
  8. ncbi The pharmacokinetic and pharmacodynamic profile of tigecycline
    Alison K Meagher
    Cognigen Corporation, Buffalo, New York, USA
    Clin Infect Dis 41:S333-40. 2005
  9. ncbi Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel
    Gerald J Fetterly
    Cognigen Corporation, Buffalo, NY 14263, USA
    Clin Cancer Res 14:5856-63. 2008
  10. ncbi The cost-effectiveness of cefepime plus metronidazole versus imipenem/cilastatin in the treatment of complicated intra-abdominal infection
    Philip S Barie
    Department of Surgery and Public Health, Weill Medical College of Cornell University, New York, New York, USA
    Surg Infect (Larchmt) 5:269-80. 2004

Collaborators

Detail Information

Publications11

  1. ncbi Challenges in the transition to model-based development
    Thaddeus H Grasela
    Cognigen Corporation
    AAPS J 7:E488-95. 2005
    ..Creating these capabilities, infrastructure, and incentivizations are critical to realizing the full value of modeling and simulation in drug development...
  2. ncbi Pharmacometrics and the transition to model-based development
    T H Grasela
    Cognigen Corporation, Williamsville, New York, USA
    Clin Pharmacol Ther 82:137-42. 2007
    ..This essay describes an approach for formalizing the pharmacometrics process using the disciplines encompassed by enterprise engineering...
  3. ncbi Informatics: the fuel for pharmacometric analysis
    Thaddeus H Grasela
    Cognigen Corporation, Buffalo, NY 14221 5831, USA
    AAPS J 9:E84-91. 2007
    ..Finally, we offer specific suggestions for performing a systematic analysis of existing challenges as an approach to defining the next generation of pharmacometric informatics...
  4. ncbi Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections
    Scott Van Wart
    Pharmacometrics R and D, Cognigen Corporation, Buffalo, New York 14221-5831, USA
    Antimicrob Agents Chemother 48:4766-77. 2004
    ....
  5. ncbi Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent
    Alison K Meagher
    Department of Clinical Pharmacology, Cognigen Corporation, Buffalo, NY 14221, USA
    Diagn Microbiol Infect Dis 52:165-71. 2005
    ....
  6. ncbi Kerfuffle!
    Thaddeus H Grasela
    Cognigen Corporation, 395 Youngs Road, Buffalo, NY 14221, USA
    J Clin Pharmacol 49:386-8. 2009
    ..They are not just an unpleasant aspect of the job that pharmacometricians must learn to live with in the conscientious execution of their work...
  7. ncbi Exposure-response analyses of tigecycline tolerability in healthy subjects
    Julie Passarell
    Pharmacologic Division, Cognigen Corporation, Buffalo, NY 14221, USA
    Diagn Microbiol Infect Dis 65:123-9. 2009
    ..26 (0.29) and 0.07 (0.11), respectively. Model-predicted rates of nausea and vomiting were comparable with those observed for the tetracycline class of antibiotics, with tolerable rates predicted after 50-mg doses of tigecycline...
  8. ncbi The pharmacokinetic and pharmacodynamic profile of tigecycline
    Alison K Meagher
    Cognigen Corporation, Buffalo, New York, USA
    Clin Infect Dis 41:S333-40. 2005
    ..The pharmacokinetics of tigecycline are also not affected by food, although tolerability is increased if the drug is administered following a meal...
  9. ncbi Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel
    Gerald J Fetterly
    Cognigen Corporation, Buffalo, NY 14263, USA
    Clin Cancer Res 14:5856-63. 2008
    ....
  10. ncbi The cost-effectiveness of cefepime plus metronidazole versus imipenem/cilastatin in the treatment of complicated intra-abdominal infection
    Philip S Barie
    Department of Surgery and Public Health, Weill Medical College of Cornell University, New York, New York, USA
    Surg Infect (Larchmt) 5:269-80. 2004
    ..Our objective was to compare the economic benefits of cefepime plus metronidazole with those of imipenem/cilastatin in the treatment of complicated intra-abdominal infections...
  11. ncbi Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction
    Paul G Ambrose
    Division of Infectious Diseases, Cognigen Corporation, Buffalo, 395 Youngs Road, Buffalo, NY 14221 5831, USA
    J Antimicrob Chemother 52:435-40. 2003
    ....